FPC
CADX

Falcon Point Capital’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Falcon Point Capital’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-113,808
Closed -$1.03M – 134
2013
Q4 		$1.03M Hold
113,808
– – 0.98% 30
2013
Q3 		$717K Buy
113,808
+21,591
+23% +$137K 0.76% 51
2013
Q2 		$629K Buy
+92,217
New +$642K 0.69% 56

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Falcon Point Capital's CADX Position: Q1 2014 in Review

Falcon Point Capital sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 113,808 shares — an estimated $1.03M sold.

Falcon Point Capital first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.03M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Falcon Point Capital reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Falcon Point Capital sold 113,808 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.03M.
  • Falcon Point Capital first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Falcon Point Capital's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.03M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Falcon Point Capital's 13F filing for Q1 2014, filed 28 Apr 2014.